SYRE Q2 2019 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$19M

Net Income

-$18M

EPS (Diluted)

$-13.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$117M

Total Liabilities

$18M

Stockholders' Equity

$100M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	$0	—
Operating Income	-$19M	-$10M	-92.6%
Net Income	-$18M	-$9M	-91.4%